RESPIRATORY
The Future of Oxygen Therapy Is About Mobility, Not Misconceptions
Understanding the difference between pulse-dose and continuous flow
By Doug Francis
For decades, oxygen therapy conversations have largely centered around one question: How do we keep patients adequately oxygenated?
Today, the better question may be: How do we keep patients oxygenated while also keeping them active, independent and engaged in daily life?
That distinction matters.
As more patients with chronic respiratory disease seek mobility and independence, providers are increasingly evaluating whether portable oxygen concentrators (POCs) and pulse-dose oxygen delivery systems can meet both clinical and lifestyle needs. Yet despite significant advances in oxygen delivery technology—and decades of supporting clinical evidence—many misconceptions about pulse-dose therapy persist.
The most common misconception is that pulse-dose oxygen delivery is inherently inferior to continuous flow.
The clinical evidence tells a far more nuanced story.
Oxygen Therapy Has Always Been About More Than Survival
The foundational studies that established long-term oxygen therapy as the standard of care in chronic obstructive pulmonary disease (COPD)—that is, the landmark Nocturanal Oxygen Therapy Trial (NOTT) and Medical Research Council working party study from the 1980s—demonstrated that patients who used oxygen for at least 15 to 18 hours per day experienced dramatically improved survival compared to those using oxygen only intermittently or nocturnally.
But one detail is often overlooked.
Patients achieved those additional daily hours of oxygen use because they were able to remain ambulatory. Portable oxygen systems enabled patients to continue moving throughout the day instead of being confined to stationary equipment.
Subsequent analyses reinforced this connection between mobility and outcomes. A follow-up review of the NOTT trial found that the survival advantage was greatest among patients who used oxygen to support increased physical activity.
That finding helped shift the industry conversation from simply helping patients survive to helping them remain functional and engaged in life.
Mobility Is a Clinical Outcome
For many respiratory patients, reduced mobility creates a dangerous cycle.
Shortness of breath leads patients to limit activity. Reduced activity contributes to physical deconditioning, isolation, anxiety, and declining overall health. Over time, sedentary behavior can increase the likelihood of exacerbations and hospitalization.
Research increasingly shows that mobility itself is closely tied to outcomes.
One large COPD study found that patients maintaining at least 150 minutes of physical activity per week had a 34% lower risk of 30-day hospital readmission compared to sedentary patients.
Even patients who were only modestly active experienced meaningful reductions in readmission risk.
Another study evaluating “life-space mobility” found that nine out of 10 oxygen-dependent COPD patients using non-portable systems failed to meet normal community mobility needs, with many patients remaining largely confined to their homes.
This is where portable oxygen concentrators can play an important role.
When patients are provided oxygen systems that support movement and daily activity, they are often more willing to remain compliant with therapy and more capable of maintaining routines outside the home. The goal is not simply oxygen delivery; it is enabling patients to continue participating in life.
The goal is not simply oxygen delivery; it is enabling patients to continue participating in life.
The Pulse-Dose Misconception
Despite growing adoption of POCs, some clinicians, caregivers, and patients continue to assume that pulse-dose oxygen delivery is clinically inferior to continuous flow. That assumption is outdated. Pulse-dose technology works differently from continuous flow, but different does not automatically mean less effective.
Continuous flow systems deliver oxygen continuously throughout both inhalation and exhalation. Pulse-dose systems deliver oxygen in concentrated bursts during the early inspiratory phase of breathing—the period when oxygen is most effectively delivered to the gas-exchange regions of the lungs.
In fact, multiple studies suggest pulse-dose delivery may actually improve oxygen efficiency by reducing oxygen waste in the anatomical dead space.
One exercise study published in the journal Thorax involving patients with severe COPD found no significant difference in oxygen saturation levels between pulse-dose and continuous-flow oxygen during maximal exertion. Patients achieved comparable endurance, walking distance and breathlessness reduction with both delivery methods.
Another large clinical study published in CHEST involving 100 hospitalized patients found that pulse-dose and continuous-flow oxygen were statistically equivalent in maintaining oxygen saturation across varied respiratory conditions, while pulse-dose systems used substantially less oxygen overall.
The key takeaway is not that pulse-dose replaces continuous flow in every scenario. It does not.
Rather, the evidence shows that properly titrated pulse-dose systems can effectively maintain oxygenation for many ambulatory patients while providing substantial advantages in portability, battery life, and usability.
Proper Titration Matters
One of the most important lessons from recent research is that oxygen therapy must be individualized.
POC settings are not interchangeable with continuous-flow liters-per-minute prescriptions. Device performance varies between manufacturers and technologies, particularly during exertion and sleep. That means patient assessment and titration remain essential.
Providers should evaluate patients not only at rest, but also during real-world activity and exertion. Successful oxygen therapy requires understanding how a patient breathes while walking, climbing stairs, shopping or performing normal daily activities.
A recent crossover study involving very severe COPD patients found that modern POC systems achieved a 96% clinical success rate during exertion when appropriately titrated.
This reinforces an important point for providers: the conversation should not focus on whether pulse-dose or continuous flow is universally “better.” The focus should instead be on selecting the right device and settings for the individual patient.
Yet, many patients who could benefit from a POC still are not receiving one, despite the evidence.
Sleep & Pulse-Dose Technology Have Evolved
Another historical concern surrounding pulse-dose oxygen involves nighttime use.
Older-generation systems sometimes struggled to reliably detect shallow breathing during sleep. Modern POC technology has significantly improved trigger sensitivity and nocturnal performance.
Recent randomized crossover trials demonstrated that contemporary pulse-dose systems were not inferior to continuous flow for maintaining nocturnal oxygen saturation in long-term oxygen therapy patients without significant obstructive sleep apnea.
Additional bench testing confirmed that modern POCs can reliably detect inhalation even during shallow breathing patterns associated with sleep and rest.
This does not eliminate the need for proper patient selection and monitoring. But it does reinforce how far oxygen delivery technology has advanced, and how critical it is that providers look beyond outdated historical perceptions and keep pace with those advances when making therapy decisions.
The Future of Oxygen Therapy Is Patient-Centered
Ultimately, oxygen therapy should not be viewed solely through the lens of equipment categories.
The goal is not simply choosing between pulse-dose and continuous flow. The goal is to help patients maintain oxygenation, mobility, confidence and quality of life over the long term.
That requires individualized assessment, careful titration, patient education and ongoing monitoring.
It also requires moving beyond outdated assumptions and provider education on evolving oxygen technologies.
Modern portable oxygen concentrators are no longer niche mobility devices. Increasingly, they are becoming an important clinical tool for improving adherence, supporting activity, and helping patients remain engaged in daily life.
Large-scale population data now suggests that patients using POCs experience fewer hospitalizations, lower overall healthcare costs and improved survival compared to patients relying solely on stationary systems or compressed gas tanks.
That does not mean every patient belongs on pulse-dose therapy. But it does mean the industry should stop viewing mobility and portability as secondary considerations.
For many patients, mobility is part of the therapy itself.
Doug Francis is CEO of Rhythm Healthcare, a leader in respiratory and mobility solutions focused on improving patient access, comfort and independence. A longtime home medical equipment industry leader, Doug has spent more than 25 years working alongside providers, clinicians and respiratory care professionals to improve oxygen access, patient mobility and quality-of-life outcomes for individuals living with chronic respiratory disease. Visit rhythmhc.com.
